A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer
Status:
Withdrawn
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This study is divided into two stages: dose escalation and dose extension, including a single
dose and a multiple dose clinical study. This is a single-center, open, non randomized,
single arm study to the safety and tolerability of TQB3015 tables in patients with advanced
malignant cancer.